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Background: Increased ventilatory response has been shown to have a high prognostic value in patients with
chronic heart failure. Our aim was therefore to determine the ventilatory efficiency in pulmonary arterial
hypertension and chronic thromboembolic pulmonary hypertension by cardiopulmonary exercise testing (CPET)
identifying PH-patients with increased risk for death within 24 months after evaluation.
Methods: 116 patients (age: 64 ± 1 years) with a mean pulmonary arterial pressure of 35 ± 1 mmHg underwent
CPET and right heart catheterization. During a follow-up of 24 months, we compared the initial characteristics of
survivors (n = 87) with nonsurvivors (n = 29).
Results: Significant differences (p≤ 0.005) between survivors and nonsurvivors existed in ventilatory equivalents for
oxygen (42.1 ± 2.1 versus 56.9 ± 2.6) and for carbon dioxide (Ve/VCO2) (47.5 ± 2.2 versus 64.4 ± 2.3). Patients with
peak oxygen uptake≤ 10.4 ml/min/kg had a 1.5-fold, Ve/VCO2≥ 55 a 7.8-fold, alveolar-arterial oxygen
difference≥ 55 mmHg a 2.9-fold, and with Ve/VCO2 slope≥ 60 a 5.8-fold increased risk of mortality in the next
24 months.
Conclusions: Our results demonstrate that abnormalities in exercise ventilation powerfully predict outcomes in PH.
Consideration should be given to add clinical guidelines to reflect the prognostic importance of ventilatory
efficiency parameters in addition to peak VO2.Background
Most patients with pulmonary hypertension (PH) have
exercise limitation attributing to an impaired vasodilator
response of the pulmonary arteries during exercise. Car-
diopulmonary exercise testing (CPET) describes the
underlying physiologic abnormalities associated with the
underperfusion of the pulmonary vascular bed seen in
PH [1-6]. Additionally, CPET allows reproducible assess-
ment of functional capacity and treatment efficacy in
patients with PH [2,5,7-10].
Peak oxygen uptake (VO2) is the most frequently ana-
lyzed CPET parameter and has consistently demon-
strated prognostic significance. Other ventilatory expired
gas parameters obtained during exercise testing have re-
cently demonstrated prognostic value. The relationship
between minute ventilation and carbon dioxide produc-
tion (Ve/VCO2 slope) is one of such CPET parameter* Correspondence: martin.schwaiblmair@klinikum-augsburg.de
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distribution, and reproduction in any mediumthat appears to have clinical value. It can be derived
from submaximal exercise testing and is independent of
patient motivation. The Ve/VCO2 slope is inversely
related to cardiac output at peak exercise [11] and is at
least partly explained by a decrease in pulmonary perfu-
sion [12,13]. Ventilatory efficiency was found to be reli-
able predictor of prognosis in patients with chronic
heart failure [14-22].
Since inefficiency of ventilation results from decreased
perfusion of the ventilated lung, for example by an
increased physiological dead space ventilation, a high
ventilatory response relative to metabolic demand would
be expected [23]. If a simple non-invasive measurement,
such as the VE/VCO2 ratio, could be shown to be useful
in evaluating pulmonary vascular disease, it might serve
to supplement other methods currently used to monitor
clinical course and treatment. At now, few studies have
investigated the relationship between exercise capacity
and VE/VCO2 slope in patients with PH [24,25].
Despite recent advances in pharmacological treatment
of patients with PH, mortality rates, especially inentral Ltd. This is an Open Access article distributed under the terms of the
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(PAH), remain high. Reliable risk stratification is a con-
tinuing challenge and the identification of patients at
highest risk for early death from right heart failure is of
special importance. Functional capacity, as defined by
peak VO2 during CPET is established as a powerful pre-
dictor of mortality in PAH [26,27] and a peak VO2
below 10.4 mL/kg/min is now considered a key criterion
for early mortality [2]. To date however, differences in
the prognostic value of peak VO2 and the Ve/VCO2
slope have not been widely emphasized.
In this study, we determine the predictive value of
ventilatory efficiency parameters for estimating the 2-
years survival of patients with pulmonary arterial hyper-
tension (PAH) and inoperable chronic thromboembolic
pulmonary hypertension (CTEPH) and compare these
parameters with survival predicted by peak VO2.Methods
Subjects
This study included consecutive patients who were re-
ferred to our PH centre from January 2005 to January
2008 to confirm and to classify the PH, as defined by the
Proceedings of the 4th World Symposium on Pulmonary
Hypertension [26]. All patients underwent right heart
catheterization (RHC) to establish the diagnosis, pul-
monary function testing, six-minute walking test and a
progressively increasing, symptom-limited CPET with
gas exchange measurements. All patients did not receive
any specific pulmonary artery medication at the begin-
ning of the study. Patients with severe concomitant
extracardiac diseases limiting exercise performance were
excluded.
All patients were followed at the PH centre, Klinikum
Augsburg, University of Munich. The outcome data
were collected by patient`s visit every 3 months. The
minimum follow-up period was 24 months.
All procedures adhered to the commonly accepted
ethical guidelines, the protocol was initially reviewed
and approved by an Ethics Committee and written
informed consent was obtained from every patient.Lung function tests
Pulmonary function tests included spirometry, body
plethysmography, and measurement of diffusing capacity
employing the single breath method (Master Screen
Body and MS-PFT, Jaeger, Cardinal Health, USA). Each
parameter was calculated as percent of predicted [28].
The following parameters were determined: forced vital
capacity (FVC), total lung capacity (TLC), forced expira-
tory volume in one second (FEV1) and diffusing capacity
for carbon monoxide (TLco). Blood gas analysis (ABL
725, Radiometer, Copenhagen, Denmark) was performedin arterialized capillary blood from the ear lobe without
supplemental oxygen [29].
Six-minute walk test
Measurement of the distance walked in 6 min was per-
formed in all patients according to the standards of the
American Thoracic Society [30]. The patients were
instructed to walk back and forth at their own pace in a
30-m corridor in order to cover as much ground as pos-
sible in the allotted time. A research assistant supervised
the test, telling the patient the remaining exercise time
every 2 min. The patients were allowed to stop and take
at rest during the test, but were instructed to resume
walking as soon as possible.
Cardiopulmonary exercise testing
CPET was performed using standardized protocol [31];
work rate was continuously increased by 5 – 15 W/min
to a maximum tolerated level on an electromagnetically
braked cycle ergometer (ViaSprint 150 p, Ergoline, Ger-
many). Patients were encouraged to exercise until symp-
toms were intolerable.
Blood gas analysis was analyzed at rest and during
maximal exercise. Heart rate was monitored continu-
ously, and non-invasive blood pressure was taken every
2 min. The maximum work rate was recorded. Oxygen
uptake (VO2), minute ventilation (Ve), and carbon diox-
ide output (VCO2) were measured breath by breath
wearing an adult facemask (Vmax spectra 229 D, Sensor
Medics, CA, USA). Peak VO2, oxygen pulse (O2 pulse)
and alveolar-arterial oxygen difference (AaDO2) were
calculated as described by Wasserman et al. [31]. The
anaerobic threshold (AT) was chosen as the VO2 at
which the Ve/VO2 increased while the Ve/VCO2
decreased or remained constant. Peak VO2 was defined
as the value of averaged data during the final 15 seconds
of exercise. The Ve/VCO2 slope was determined as the
linear regression slope of Ve and VCO2 from the start
of exercise until the RC point (the time at which ventila-
tion is stimulated by CO2 output and end-tidal CO2
tension begins to decrease) [31].
Right heart catheterization
All patients underwent RHC. Patients received no medi-
cations on the morning of the procedure, resulting in a
discontinuation of treatment with medication of about
12 h. A True Size Thermodilution Catheter (“S” Tip
Catheter, Edwards Lifesciences, Irvine, CA, USA) was
inserted via the right femoral vein. Hemodynamic mea-
surements were performed in supine position and
included heart rate, pressure in wedge-position (PCWP),
pulmonary arterial pressure (PAP) and right atrium pres-
sure (RA). Oxygen saturation (SO2) was measured in
mixed venous blood samples (ABL 725, Radiometer,
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obtained using the thermodilution method (Com-2, Car-
diac Output Computer, Edwards Lifesciences, Irvine,
CA, USA). CI and pulmonary vascular resistance (PVR)
were calculated using standard formulas [PVR= (mPAP –
PCWP)/Q].
Statistical analysis
Continuous date were presented as the mean ± standard
error of mean (SEM); categorical data were presented as
percentages of patients in each category. A statistical
software package (SPSS, version 12.0 for Windows;
SPSS; Chicago, IL) was used for analysis. All results were
tested for two-sided significance. Patients were divided
in two different groups regarding the outcome after
24 months. The measured variables were compared in
the group of survivors versus the group of nonsurvivors
using the Student t-test for unpaired probes.
Simple linear regression analysis was used to examine
ve versus VCO2 slope. Test analysis was performed to
calculate sensitivity, specificity for the different threshold
values.
Furthermore, we used the Wald test to test for the sig-
nificance of odds ratio. The ability of CPET parametersTable 1 Characteristics, haemodynamics and Cardiopulmonar
(n =116) and between patients with PAH (n= 85) and those w
Overall
(n = 116)
Age (years) 61.5 ± 1.5
Sex (% female) 66
BMI (kg/m2) 25.8 ± 0.5
PAP, mmHg 39.9 ± 2.5
CI, L*min-1*m-2 2.48 ± 0.07
PVR, dynes * s * cm-5 648.2 ± 40.2
RAP, mmHg 7.28 ± 0.49
W, watts 56.2 ± 3.1
VO2, ml/min/kg 14.4 ± 0.7
AT, ml/min/kg 9.53 ± 0.40
O2 pulse, ml/min/beat 8.98 ± 0.36
Ve/VO2 - AT 41.1 ± 1.1
Ve/VCO2 - AT 47.2 ± 1.1
AaDO2 (peak exercise) mmHg 49.3 ± 1.6
a-et CO2, mmHg 5.7 ± 0.5





Ve/VO2=oxygen equivalent at anaerobic threshold.
Ve/VCO2= carbon dioxide equivalent at anaerobic threshold.
AaDO2 = alveolar-arterial oxygen difference at peak exercise.
a-et CO2= arterial-endexpiratory carbon dioxide difference at peak pexercise.
Ve – VCO2 slope = slope of minute ventilation versus carbon dioxide output.to identify the risk of mortality was assessed by compari-
son of receiver-operating characteristic curves (AUC=
area under curve). We create survival curves using the
method of Kaplan and Meier and compare the survival
curves using the log-rank test.




The study included 116 patients; there were 73 women
and 43 men with a mean age of 63.7 ± 1.7 years and a
body mass index of 26.7 ± 0.4 kg/m². According to the
ESC/ERS guidelines [27], we diagnosed 85 patients as
PAH and 31 as inoperable CTEPH [Table 1]. At the ini-
tial visit, all patients fulfilled the criterion to begin a spe-
cific drug therapy. During follow-up, the specific drug
therapy consisted calcium channel blockers in 7%,
inhaled prostanoids in 13%, endothelin receptor antago-
nists in 72% and 56% patients were treated with
phosphodiesterase type-5 inhibitors. None of the
patients was lost to follow-up. During the follow-up
period of 24 months, 29 patients died (n = 21 in the
PAH-group and n = 8 in the CTEPH-group). Causes ofy exercise parameters at baseline of the overall group
ith CTEPH (n =31)
PAH CTEPH p
(n= 85) (n = 31)
59.9 ± 1.9 66.4 ± 2.0 p = 0.064
70 55 ns
25.7 ± 0.6 26.2 ± 0.7 ns
40.5 ± 1.7 38.3 ± 3.1 ns
2.58 ± 0.08 2.22 ± 0.11 p = 0.021
647.9 ± 45.1 648.9 ± 87.5
ns
7.01 ± 0.56 8.07 ± 1.00 ns
55.2 ± 3.7 59.1 ± 5.5 ns
14.5 ± 0.8 14.1 ± 1.2 ns
9.56 ± 0.48 9.45 ± 0.72 ns
8.71 ± 0.40 9.72 ± 0.81 ns
40.9 ± 1.2 41.8 ± 2.3 ns
47.0 ± 1.2 47.8 ± 2.5 ns
51.6 ± 1.9 43.2 ± 2.9 p = 0.019
5.2 ± 0.5 7.0 ± 1.0 ns
46.6 ± 2.3 47.9 ± 3.9 ns
Table 2 Hemodynamics and Cardiopulmonary exercise
characteristics at baseline between survivors and
nonsurvivors in patients with selective drug therapy
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spiratory failure (n = 10), pulmonary hemorrhage (n = 2),
arrhythmia (n = 2) and others (n = 3).(survival after 24 months)
Survivors Nonsurvivors p
(n= 87) (n = 29)
PAP, mmHg 42.0 ± 2.5 39.6 ± 2.6 ns
CI, L*min-1*m-2 2.30 ± 0.12 2.31 ± 0.21 ns
PVR, dynes * s * cm-5 633.8 ± 68.2 594.1 ± 76.6 ns
RAP, mmHg 7.22 ± 0.79 8.55 ± 1.88 ns
W, watts 67.7 ± 8.0 35.7 ± 1.5 0.023
VO2, ml/min/kg 14.6 ± 1.4 10.9 ± 1.0 ns
AT, ml/min/kg 9.65 ± 0.87 7.09 ± 1.07 nsLung function test
Lung function tests showed no relevant restrictive lung
disease with FVC of 80.0 ± 1.5% and TLC of 91.0 ± 1.4%.
The ratio of FEV1/FVC x 100 showed no signs of rele-
vant obstructive lung disease in all patients (70.3 ± 0.9%).
The diffusing capacity was slightly reduced, to 71.4 ± 2.1
predicted. Blood gas analysis showed a mild hypoxemia
(pO2 of 63.6 ± 1.0 mm Hg) and hypocapnia (pCO2 of
33.8 ± 0.4 mm Hg).O2 pulse, ml/min/beat 9.80 ± 0.81 7.79 ± 0.64 ns
Ve/VO2 - AT 42.1 ± 2.1 56.9 ± 2.6 0.001
Ve/VCO2 - AT 47.5 ± 2.2 64.4 ± 2.3 < 0.001
AaDO2 – peak exercise, mmHg 52.8 ± 2.8 67.5 ± 4.2 0.009
a-et CO2, mmHg 6.8 ± 0.8 10.5 ± 1.1 0.014
Ve/VCO2 slope 47.0 ± 3.2 65.4 ± 7.5 0.014Hemodynamics
At initial visit and at rest, PAP was elevated (41.4± 2.5 mm
Hg), consecutively with a PVR of 624±70 dynes * s *cm-5,
and with a normal PCWP of 9.6±0.4 mmHg. The RAP
was elevated with 7.6± 1.1 mm Hg.PAP=mean pulmonary artery pressure.
CI= cardiac index.
PVR=pulmonary vascular resistance.





Ve/VO2=oxygen equivalent at anaerobic threshold.
Ve/VCO2= carbon dioxide equivalent at anaerobic threshold.
AaDO2 = alveolar-arterial oxygen difference at peak exercise.
a-et CO2= arterial-endexpiratory carbon dioxide difference at peak pexercise.
Ve – VCO2 slope= slope of minute ventilation versus carbon dioxide output.Cardiopulmonary exercise test and six minute walk
distance
Most patients showed a reduction in work capacity of
58.8 ± 26.4% with a diminished aerobic capacity of
62.2 ± 2.1% (13.6 ± 1.3 ml/min/kg), a reduced O2 pulse
of 9.3 ± 0.8 ml/min/beat and elevated ventilatory equiva-
lents for oxygen (45.9 ± 2.2) and for carbon dioxide
(51.8 ± 2.2) at the AT (9.0 ± 0.9 ml/min/kg). Furthermore,
we observed elevated AaDO2 (56.5 ± 3.2 mmHg) during
peak exercise with an elevated a-etCO2 - difference of
7.7 ± 0.9 mmHg. Ve/VCO2 slope amounted to 51.7 ± 4.3
with a PetCO2 of 28.0 ± 0.7 mmHg at peak exercise. The
AT could not be determined in 11 patients because of
mitigating oscillatory gas exchange patterns or prema-
ture end of exercise.
On average, we objectified a six minute walk distance
of 314.5 ± 12.3 m or 62.4 ± 2.2% respectively.Evaluation of survivors and nonsurvivors in respect of
CPET parameters in patients with pulmonary
hypertension
In our study group, no significant differences in any of
hemodynamic parameters, aerobic capacity, anaerobic
threshold and oxygen pulse at baseline existed between
survivors and nonsurvivors. On the other hand, signifi-
cant differences could be demonstrated in the following
parameters at baseline: power capacity (67.7 versus 35.7
watts, p = 0.023), Ve/VO2 (42.1 versus 56.9, p = 0.001),
Ve/VCO2 (47.5 versus 64.4, p< 0.001), AaDO2 (52.8
versus 67.5 mmHg, p = 0.009) and Ve/VCO2 slope (47.0
versus 65.4, p = 0.014) [Table 2].Cardiopulmonary exercise parameters predictors of
two-years mortality
According to the study results from Wensel at al. [2], we
firstly investigated the aerobic capacity with a cut-off
value of 10.4 ml/min/kg. In our study population, VO2
(AUC=0.252) could not predict the two-years mortality
with a sensitivity of 27% and specificity of 69%. The best
predictive value in our group was the Ve/VCO2 (with a
cut-off value of 55, AUC= 0,769) with a relative risk of
two-years mortality of 7.83 and a sensitivity of 80% and
a specificity of 79% [Figure 1]. Furthermore, Ve/VCO2
slope (AUC= 0.798) with a relative risk of 5.75 showed
significant predictive mortality values [Figure 2]. AaDO2
(AUC=0.758) and a-etCO2 (AUC= 0.804) values at peak
exercise was not able to predict the mortality because of
a decreased specificity of 62%/69% [Table 3].Discussion
To our knowledge, this is one of the first studies of
CPET data in patients with PAH/CTEPH to compare
ventilatory efficiency parameters as a predictor of 24-
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Figure 1 Kaplan-Meier plot relating survival to Ve/VCO2 slope.
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value of 55 identifies patients with an over seven fold
increased risk of death within 24 months after initial
evaluation. The Ve/VCO2 slope with a cutoff value of 60
had an over five fold increased risk of death within the
same time interval. In our study group the parameters of
ventilatory efficiency significantly better predicted the
clinical outcome compared to peak oxygen uptake with
a cut-off value of 10.4 ml/min/kg. Taken together, these
results support the concept that for example the VE/
VCO2 slope or the ventilatory equivalents may be prog-
nostically superior to peak VO2.
Symptoms in PAH-patients develop during exercise
because recruitment of pulmonary vascular bed needed
for exercise is impaired. Three pathophysiologies could
be easily identified: [1] failure to perfuse the ventilated
lung, thereby increasing the physiologic dead space and
ventilatory requirement [5,24,32]; [2] failure to increase
cardiac output (oxygen transport) appropriately in re-
sponse to exercise, causing a low work rate lactic acid-
osis (increased CO2 production relative to O2
consumption), thereby increasing acid ventilatory drive
[11,33]; and [3] exercise-induced hypoxemia in most PH
patients, thereby increasing the hypoxic ventilatory
drive. Ventilatory inefficiency could be measured as an
increase in ventilatory equivalents for oxygen and carbon
dioxide. Reindl et al. [11] showed that ventilatoryTable 3 Cardiopulmonary exercise parameters predictors of t
selective drug therapy, ie, in patients with pulmonary artery
thromboembolic pulmonary hypertension (n =116)
Sensitivity Specificit
VO2 (< 10.4 ml/min/kg) 27% 69%
Ve/VCO2 (≥ 55) 80% 79%
AaDO2 (≥ 55 mmHg) 69% 62%
Ve/VCO2 slope (≥ 60) 70% 81%
a-etCO2 (≥ 8 mmHg) 62% 69%efficiency is influenced by cardiac output and by pul-
monary vasoconstriction. Alveolar hypoperfusion, caused
by impaired or defective vasodilation, probably repre-
sents the link to the impairment of ventilatory efficiency.
A significant finding in our study was the confirmation
that Ve/VCO2 slope is a strong, independent predictor
of death in patients suffering from PAH/CTEPH. This
observation is in agreement with other studies from
patients with chronic heart failure which have examined
the prognostic significance of the Ve/VCO2 slope
[15,19,34,35]. Patients with chronic heart failure venti-
late more during exercise than controls, resulting in an
increase in the Ve/VCO2 slope [36]. The increased Ve/
VCO2 slope could be a result of different mechanism.
Ventilation perfusion mismatch [12,37], impaired diffu-
sion of metabolic gases [38], respiratory muscle weak-
ness [39], and heightened sensitivity of peripheral
receptors [40,41] have all been postulated as possible
causes. Additionally, one of the proposed mechanisms
for an increase in Ve/VCO2 slope in chronic heart fail-
ure patients is an abnormal pulmonary perfusion [42].
Furthermore, Ukkonen et al. [43] showed that the right
ventricular oxidative metabolism correlates with Ve/
VCO2 slope in chronic heart failure patients. This sup-
ports the hypothesis that pulmonary vascular resistance
is a main determinant of the Ve/VCO2 slope [43].wo-years mortality rate in patients in patients with
hypertension and in patients with chronic
y odds ratio significance
[95% confidence interval]
1.88 [1,58; 2,18] p = 0.03
14.66 [12,70; 16,62] p = 0.004
3.67 [3,11; 4,23] p = 0.09
9.92 [6,68; 13,17] p = 0.03
3.63 [2,73; 4,53] p = 0.02
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in PH, pulmonary blood flow (cardiac output) fails to in-
crease normally during exercise. The blunted cardiac
output response to exercise results in an increase in an-
aerobic glycolysis with development of a lactic acidosis
at low work rates. The lactic acidosis produces acid
stimuli that increases ventilatory drive [44].
Mitani et al. [25] suggested that it is necessary – when
performing a CPET in PAH patients – to observe not
only VO2 or VCO2, but also Ve/VCO2, in order to pre-
vent aggravation of the ventilation/perfusion inequality,
which leads to exercise-induced hypoxemia. A higher
VE/VCO2 ratio describes a greater ventilatory require-
ment for eliminating the CO2 produced by aerobic me-
tabolism and defines a reduced ventilatory efficiency.
The reduced ventilatory efficiency is therefore caused by
an increase in physiological dead space and a reduced
PaCO2 set-point [45]. Ting et al. [23] demonstrated that
patients with higher Ve/VCO2 ratio would be patients
with higher pulmonary vascular resistance. On the other
side, the authors showed that the improvement in VE/
VCO2 ratio paralleled the improvement in VD/VT fol-
lowing dosing with prostanoids. This supports the con-
cept that a reduction in Ve/VCO2 ratio reflects an
improvement in blood flow to the ventilated lung. Rey-
brouck et al. [24] found that the Ve/VCO2 slope was
steeper in patients with PH than the slope in patients
with normal PAP, and these authors found a significant
correlation between the slope and PAP and the VD/VT.
Because of ventilation-perfusion inequalities, the VD/VT
is increased, making gas exchange less efficient than nor-
mal. This causes PetCO2 to be diluted relative to
PaCO2. Because pulmonary vascular disease is the hall-
mark of patients with PH, it is likely that the remarkably
low PetCO2 seen in our patients with PH is partially due
to underperfusion of ventilated lung.
Our data indicate that abnormally reduced ventilatory
efficiency parameters are powerful and independent pre-
dictors of mortality in patients with PAH/CTEPH. Our
study demonstrates that an increased ventilatory re-
sponse to exercise is associated with a lower survival in
patients with stable PAH. For several years, peak VO2
was the “gold standard” and remains widely used to risk
stratify this type of patients [2]. However, the limitations
of peak VO2 have prompted the search for other indices
of CPET that can serve as alternative prognostic factors.
The main disadvantage of peak VO2 is the need for
maximal exercise, which may be difficult to achieve, par-
ticularly in PAH patients, whose daily activity levels are
far below the effort required by the test. In addition,
peak VO2 may be underestimated because of low patient
motivation or because of premature termination of the
test by the physician. Thus supplementary indices are
needed to sharpen the risk stratification [46]. Unlikepeak VO2, for example the Ve/VCO2 slope is generally
independent from subject effort. In addition, variation in
the Ve/VCO2 slope appears to rely closely on central
function in patients with PH. The closer reliance the Ve/
VCO2 slope has on cardiac performance may contribute
to its prognostic accuracy relative to peak VO2.
Conclusion
The ventilatory efficiency parameters are easily measur-
able and highly reproducible parameters obtained from
CPET, and the prognostic value of a reduced ventilatory
efficiency suggests higher than the peak VO2 alone.
Thus, a rational and pragmatic risk stratification process
should include both peak VO2 and ventilatory efficiency
parameters, and in particular, the measurement of the
Ve/VCO2 slope and ventilatory equivalent for carbon di-
oxide should be performed in patients with PAH/
CTEPH. In summary, based upon these preliminary
results, we propose that these indices of CPET might be
helpful in the care of these patients and could play a role
as a prognostic effort-independent marker in the evalu-
ation of PAH/CTEPH patients.
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